Trexquant Investment LP Takes Position in Iovance Biotherapeutics Inc (IOVA)

Trexquant Investment LP bought a new position in Iovance Biotherapeutics Inc (NASDAQ:IOVA) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 39,590 shares of the biotechnology company’s stock, valued at approximately $307,000. Trexquant Investment LP owned approximately 0.05% of Iovance Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the business. Legal & General Group Plc bought a new stake in Iovance Biotherapeutics in the second quarter worth approximately $103,000. Swiss National Bank increased its holdings in Iovance Biotherapeutics by 17.4% in the third quarter. Swiss National Bank now owns 104,600 shares of the biotechnology company’s stock worth $811,000 after purchasing an additional 15,500 shares in the last quarter. Parametric Portfolio Associates LLC bought a new stake in Iovance Biotherapeutics in the second quarter worth approximately $125,000. Dynamic Technology Lab Private Ltd bought a new stake in Iovance Biotherapeutics in the third quarter worth approximately $133,000. Finally, Bank of New York Mellon Corp increased its holdings in Iovance Biotherapeutics by 7.1% in the third quarter. Bank of New York Mellon Corp now owns 261,692 shares of the biotechnology company’s stock worth $2,028,000 after purchasing an additional 17,338 shares in the last quarter. Institutional investors and hedge funds own 75.93% of the company’s stock.

Several equities research analysts have recently commented on the company. BidaskClub downgraded Iovance Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Iovance Biotherapeutics in a report on Monday, November 13th. B. Riley restated a “buy” rating and set a $18.00 price objective on shares of Iovance Biotherapeutics in a report on Monday, November 13th. Oppenheimer restated a “buy” rating and set a $13.00 price objective on shares of Iovance Biotherapeutics in a report on Monday, November 13th. Finally, Zacks Investment Research downgraded Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 3rd. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $14.53.

Shares of Iovance Biotherapeutics Inc (NASDAQ IOVA) opened at $8.35 on Wednesday. Iovance Biotherapeutics Inc has a 1-year low of $4.45 and a 1-year high of $9.18.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01). equities research analysts forecast that Iovance Biotherapeutics Inc will post -1.37 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2017/12/06/trexquant-investment-lp-takes-position-in-iovance-biotherapeutics-inc-iova.html.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics Inc (NASDAQ:IOVA).

Institutional Ownership by Quarter for Iovance Biotherapeutics (NASDAQ:IOVA)

What are top analysts saying about Iovance Biotherapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Iovance Biotherapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit